Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Challenges associated with curcumin therapy in Alzheimer disease
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
C (101 MHz, MeOD): 174.48 (C), 172.98 (C), 172.60 (C), 172.27 (C), 171.50 (C), 162.11 (q, J = 35.7 Hz, (C), 135.77 (t, J = 23.8 Hz, CD)), 134.37 (td, J = 25.0, 9.9 Hz, CD), 131.03 (td, J = 25.1, 12.5 Hz, CD), 119.69 (d, J = 86.2 Hz, C), 116.02 (q, J = 284.5 Hz, C) 54.03 (CH), 53.49 (CH), 41.81 (CH 2 ), 40.10 (CH 2 ), 36.20 (CH 2 ), 35.25 (CH 2 ), 32.35 (CH 2 ), 29.44 (CH 2 ), 28.70 (d, J = 16.9 Hz, CH 2 ), 27.05 (CH 2 ), 23.13 (d, J = 4.3 Hz, CH 2 ), 22.67 (d, J = 51.3 Hz, CH 2 )
(6) Riessland M, Orr ME
US$ 21.17
US$ 20.40
US$ 20.75
